EUVIMEDEUVIMED entdecken
Editorial

Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care

R Sacks, S Gandhi

Annals of Oncology · 2026-05 · 37 (5) · 579-582

DOI: 10.1016/j.annonc.2026.02.005 ↗

Kurz gefasst

Editorial in der Zeitschrift Annals of Oncology, 2026-05. Verfasst von R Sacks und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, USA. Die Arbeit nennt 23 Literaturangaben. Gefördert von: NCI NIH HHS, National Center for Advancing Translational Sciences, National Cancer Institute.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, USA.
  • Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, USA. Electronic address: Shipra.gandhi@emory.edu.

Förderung

  • NCI NIH HHS
  • National Center for Advancing Translational Sciences
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Sacks, R., & Gandhi, S. (2026). Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care. Annals of Oncology, 37(5), 579-582. https://doi.org/10.1016/j.annonc.2026.02.005

Vancouver

Sacks R, Gandhi S. Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care. Annals of Oncology. 2026;37(5):579-582. doi:10.1016/j.annonc.2026.02.005

BibTeX
@article{Sacks2026,
  author = {Sacks, R and Gandhi, S},
  title = {Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care},
  journal = {Annals of Oncology},
  year = {2026},
  volume = {37},
  number = {5},
  pages = {579--582},
  doi = {10.1016/j.annonc.2026.02.005}
}
Kostenlos starten →